Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EW NYSE:IQV NASDAQ:ISRG NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWEdwards Lifesciences$82.39+1.2%$81.48$72.30▼$87.89$46.86B0.875.37 million shs4.18 million shsIQVIQVIA$172.86+2.2%$170.03$134.65▼$247.04$28.23B1.181.76 million shs1.20 million shsISRGIntuitive Surgical$439.92+4.5%$462.50$417.74▼$603.88$149.15B1.512.44 million shs2.12 million shsJNJJohnson & Johnson$228.80+0.9%$234.91$149.04▼$251.71$545.74B0.277.74 million shs10.14 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWEdwards Lifesciences+1.28%+6.84%+1.69%+5.10%+5.74%IQVIQVIA+1.95%-0.38%-2.05%+5.12%+21.17%ISRGIntuitive Surgical+4.46%+4.73%-6.24%-10.83%-21.94%JNJJohnson & Johnson+0.88%+3.36%-2.34%-5.82%+51.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWEdwards Lifesciences$82.39+1.2%$81.48$72.30▼$87.89$46.86B0.875.37 million shs4.18 million shsIQVIQVIA$172.86+2.2%$170.03$134.65▼$247.04$28.23B1.181.76 million shs1.20 million shsISRGIntuitive Surgical$439.92+4.5%$462.50$417.74▼$603.88$149.15B1.512.44 million shs2.12 million shsJNJJohnson & Johnson$228.80+0.9%$234.91$149.04▼$251.71$545.74B0.277.74 million shs10.14 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWEdwards Lifesciences+1.28%+6.84%+1.69%+5.10%+5.74%IQVIQVIA+1.95%-0.38%-2.05%+5.12%+21.17%ISRGIntuitive Surgical+4.46%+4.73%-6.24%-10.83%-21.94%JNJJohnson & Johnson+0.88%+3.36%-2.34%-5.82%+51.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWEdwards Lifesciences 2.79Moderate Buy$95.6516.10% UpsideIQVIQVIA 3.00Buy$225.6930.56% UpsideISRGIntuitive Surgical 2.67Moderate Buy$579.3331.69% UpsideJNJJohnson & Johnson 2.74Moderate Buy$253.0410.60% UpsideCurrent Analyst Ratings BreakdownLatest ISRG, EW, IQV, and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026ISRGIntuitive Surgical Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$650.00 ➝ $520.005/13/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform5/13/2026JNJJohnson & Johnson Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$265.005/7/2026IQVIQVIA Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$225.005/4/2026IQVIQVIA Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/27/2026EWEdwards Lifesciences BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$104.00 ➝ $110.004/24/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B+) ➝ Buy (B)4/24/2026EWEdwards Lifesciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$89.00 ➝ $90.004/24/2026EWEdwards Lifesciences EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$93.004/24/2026EWEdwards Lifesciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$87.00 ➝ $85.004/24/2026EWEdwards Lifesciences Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$85.00 ➝ $87.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWEdwards Lifesciences$6.07B7.82$2.89 per share28.54$17.81 per share4.63IQVIQVIA$16.31B1.77$18.25 per share9.47$38.93 per share4.44ISRGIntuitive Surgical$10.06B15.48$9.69 per share45.39$50.52 per share8.71JNJJohnson & Johnson$94.19B5.85$14.25 per share16.06$33.85 per share6.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWEdwards Lifesciences$1.07B$1.8843.8224.592.0417.39%15.19%11.71%7/23/2026 (Estimated)IQVIQVIA$1.36B$8.0721.4213.381.628.33%30.50%6.53%7/28/2026 (Estimated)ISRGIntuitive Surgical$2.86B$8.2553.3244.843.3628.15%15.98%14.07%7/28/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6526.4518.192.2221.83%32.60%13.29%7/15/2026 (Estimated)Latest ISRG, EW, IQV, and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026IQVIQVIA$2.83$2.90+$0.07$1.61$4.10 billion$4.15 billion4/23/2026Q1 2026EWEdwards Lifesciences$0.7280$0.78+$0.0520$0.66$1.60 billion$1.65 billion4/21/2026Q1 2026ISRGIntuitive Surgical$2.08$2.50+$0.42$2.28$2.62 billion$2.77 billion4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEWEdwards LifesciencesN/AN/AN/AN/AN/AIQVIQVIAN/AN/AN/AN/AN/AISRGIntuitive SurgicalN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.202.27%+5.25%60.12%64 YearsLatest ISRG, EW, IQV, and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.23%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWEdwards Lifesciences0.064.423.63IQVIQVIA2.200.750.75ISRGIntuitive SurgicalN/A4.613.59JNJJohnson & Johnson0.461.030.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWEdwards Lifesciences79.46%IQVIQVIA89.62%ISRGIntuitive Surgical83.64%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipEWEdwards Lifesciences0.31%IQVIQVIA1.70%ISRGIntuitive Surgical0.60%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWEdwards Lifesciences16,000575.80 million574.02 millionOptionableIQVIQVIA93,000166.90 million164.06 millionOptionableISRGIntuitive Surgical17,021354.16 million352.04 millionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableISRG, EW, IQV, and JNJ HeadlinesRecent News About These CompaniesResona Asset Management Co. Ltd. Cuts Position in Johnson & Johnson $JNJ59 minutes ago | marketbeat.comProfund Advisors LLC Acquires 9,285 Shares of Johnson & Johnson $JNJ1 hour ago | marketbeat.comJohnson & Johnson $JNJ Shares Sold by ProShare Advisors LLC1 hour ago | marketbeat.comHandelsbanken Fonder AB Increases Position in Johnson & Johnson $JNJ3 hours ago | marketbeat.comJohnson & Johnson $JNJ Shares Sold by HighTower Advisors LLC3 hours ago | marketbeat.comEnvestnet Portfolio Solutions Inc. Increases Position in Johnson & Johnson $JNJ3 hours ago | marketbeat.comJohnson & Johnson $JNJ Shares Sold by Gabelli Funds LLC3 hours ago | marketbeat.comIs Johnson & Johnson (JNJ) One of the Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026?May 18 at 7:53 PM | finance.yahoo.comIs Johnson & Johnson (JNJ) One of the Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026?May 18 at 6:30 PM | insidermonkey.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18 at 1:01 PM | zacks.comWhy Johnson & Johnson (JNJ) is a Great Dividend Stock Right NowMay 18 at 12:47 PM | zacks.comSupreme Court Rejects Drugmakers’ Challenge to Medicare Price Negotiation ProgramMay 18 at 10:30 AM | quiverquant.comQ[Latest] Global Orthopedic Soft Tissue Repair Market Size/Share Worth USD 15.38 Billion by 2035 at a 9.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)May 18 at 9:51 AM | finance.yahoo.comRutgers Business School propels graduating student into Johnson & Johnson leadership programMay 18 at 9:51 AM | finance.yahoo.comNanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung CancerMay 18 at 9:10 AM | tipranks.com5,317 Shares in Johnson & Johnson $JNJ Acquired by Spectrum Strategic Capital Management LLCMay 18 at 6:38 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by TD Private Client Wealth LLCMay 18 at 6:15 AM | marketbeat.comNorth Dakota State Investment Board Takes $17.08 Million Position in Johnson & Johnson $JNJMay 18 at 5:48 AM | marketbeat.comRossmore Private Capital Acquires 14,527 Shares of Johnson & Johnson $JNJMay 18 at 5:41 AM | marketbeat.comEubel Brady & Suttman Asset Management Inc. Has $17.41 Million Stock Position in Johnson & Johnson $JNJMay 18 at 3:57 AM | marketbeat.comAbacus Wealth Partners LLC Raises Position in Johnson & Johnson $JNJMay 18 at 3:04 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks to Buy in May Before the Next AI Surge HitsBy Thomas Hughes | May 1, 2026Roblox Stock Slides to New Low as Safety Changes Weigh on OutlookBy Jennifer Ryan Woods | May 3, 2026Could These 3 New-to-Market Quantum Computing Firms Threaten D-Wave?By Nathan Reiff | April 19, 2026Verizon’s Signal Strength: The Turnaround Call Is Loud and ClearBy Jeffrey Neal Johnson | April 30, 2026NVIDIA’s China Connection: Investor Risks With Earnings AheadBy Thomas Hughes | May 5, 2026ISRG, EW, IQV, and JNJ Company DescriptionsEdwards Lifesciences NYSE:EW$82.39 +1.01 (+1.24%) Closing price 05/18/2026 03:59 PM EasternExtended Trading$81.01 -1.38 (-1.68%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.IQVIA NYSE:IQV$172.86 +3.74 (+2.21%) Closing price 05/18/2026 03:59 PM EasternExtended Trading$173.58 +0.71 (+0.41%) As of 07:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.Intuitive Surgical NASDAQ:ISRG$439.92 +18.80 (+4.46%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$439.56 -0.37 (-0.08%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.Johnson & Johnson NYSE:JNJ$228.80 +2.09 (+0.92%) Closing price 05/18/2026 03:59 PM EasternExtended Trading$229.05 +0.25 (+0.11%) As of 07:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
